HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors

Olsen, 2007, Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma, J. Clin. Oncol., 25, 3109, 10.1200/JCO.2006.10.2434 Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid: SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, 109, 31, 10.1182/blood-2006-06-025999 Piekarz, 2009, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J. Clin. Oncol., 27, 5410, 10.1200/JCO.2008.21.6150 Whittaker, 2010, Final results from a multicenter international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, J. Clin. Oncol., 28, 4485, 10.1200/JCO.2010.28.9066 Khan, 2010, HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy, Proc. Natl. Acad. Sci. U. S. A., 107, 6532, 10.1073/pnas.0913912107 New, 2013, A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors, Cell Death Differ., 20, 1306, 10.1038/cdd.2013.47 Fujii, 2012, Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target in combination with histone deacetylase inhibitors, for lymphoid neoplasms, J. Proteom., 75, 1401, 10.1016/j.jprot.2011.11.010 Jaattela, 1998, Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases, EMBO J., 17, 6124, 10.1093/emboj/17.21.6124 Santarosa, 1997, Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients, Eur. J. Cancer, 33, 873, 10.1016/S0959-8049(97)00002-6 Trieb, 1998, Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy, Hum. Pathol., 29, 1050, 10.1016/S0046-8177(98)90412-9 de Bono, 2008, Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors, Clin. Cancer. Res., 14, 6663, 10.1158/1078-0432.CCR-08-0376 Stühmer, 2010, Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585, Br. J. Haematol., 149, 529, 10.1111/j.1365-2141.2010.08126.x Faraco, 2006, Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain, Mol. Pharmacol., 70, 1876, 10.1124/mol.106.027912 Li, 2011, Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock, J. Biomed. Biotechnol., 2011, 523481, 10.1155/2011/523481 Kaiser, 2011, Antileukemic activity of the HSP70 inhibitor pifithrin-mu in acute leukemia, Blood Cancer J., 1, e28, 10.1038/bcj.2011.28 Brimmell, 1998, BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability, Oncogene, 16, 1803, 10.1038/sj.onc.1201704 Gabai, 2005, Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents, Oncogene, 24, 3328, 10.1038/sj.onc.1208495 Yang, 2012, Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells, Cancer Lett., 321, 137, 10.1016/j.canlet.2012.01.030 Takahashi, 2016, Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells, Cancer Lett., 378, 8, 10.1016/j.canlet.2016.05.002 Faure, 2004, Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes, Int. J. Cancer, 108, 863, 10.1002/ijc.11653 Scaffidi, 1998, Two CD95 (APO-1/Fas) signaling pathways, EMBO J., 17, 1675, 10.1093/emboj/17.6.1675 Li, 1998, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, 94, 491, 10.1016/S0092-8674(00)81590-1 Shawgo, 2009, Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells, J. Biol. Chem., 284, 33447, 10.1074/jbc.M109.032359 Johnson, 2002, Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70, J. Biol. Chem., 277, 9590, 10.1074/jbc.M107942200 Kee, 2008, Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy, Circ. Res., 103, 1259, 10.1161/01.RES.0000338570.27156.84 Marks, 2000, Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells, J. Natl. Cancer Inst., 92, 1210, 10.1093/jnci/92.15.1210 Jego, 2013, Targeting heat shock proteins in cancer, Cancer Lett., 332, 275, 10.1016/j.canlet.2010.10.014 Nylandsted, 2000, Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2, Proc. Natl. Acad. Sci. U. S. A., 97, 7871, 10.1073/pnas.97.14.7871 Nylandsted, 2000, Heat shock protein 70 is required for the survival of cancer cells, Ann. N Y Acad. Sci., 926, 122, 10.1111/j.1749-6632.2000.tb05605.x